Ballas Samir K
Cardeza Foundation for Hematologic Research, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
J Clin Med. 2021 Jan 23;10(3):438. doi: 10.3390/jcm10030438.
Sickle cell disease (SCD) is an inherited disorder of hemoglobin structure. The clinical effects of the sickle gene are pleiotropic in nature causing multiple phenotypic expressions associated with the various complications of the disease. The hallmark of the disease is pain that could be acute, chronic, nociceptive, or neuropathic that could occur singly or in various combinations. The acute vaso-occlusive painful crisis (VOC) is the most common cause of admissions to the Emergency Department and/or the hospital. Although progress has been made in understanding the pathophysiology of SCD as well as in developing preventive and curative therapies, effective pain management continues to lag behind and depend mostly on the use of opioids. This review describes the history of opioids from the ancient times of opium to the current use of the many controversial opioids. In addition, the major cause of death of patients with SCD is the complications of the disease itself and not the use of opioids. The use of opioids by patients with SCD has been stable over the years. Judicious use of opioids to treat sickle cell pain according to available guidelines could minimize the unnecessary suffering experienced by patients with SCD.
镰状细胞病(SCD)是一种血红蛋白结构的遗传性疾病。镰状基因的临床效应具有多效性,会导致与该疾病各种并发症相关的多种表型表达。该疾病的标志是疼痛,疼痛可能是急性、慢性、伤害性或神经性的,可单独出现或多种情况同时出现。急性血管阻塞性疼痛危机(VOC)是急诊科和/或医院收治患者的最常见原因。尽管在理解SCD的病理生理学以及开发预防和治疗方法方面取得了进展,但有效的疼痛管理仍然滞后,并且主要依赖于阿片类药物的使用。本综述描述了从古代鸦片到当前使用的众多有争议的阿片类药物的阿片类药物历史。此外,SCD患者的主要死因是疾病本身的并发症,而非阿片类药物的使用。多年来,SCD患者对阿片类药物的使用一直保持稳定。根据现有指南明智地使用阿片类药物治疗镰状细胞疼痛,可以将SCD患者遭受的不必要痛苦降至最低。